CA2780382A1 - Pemirolast for the treatment of systemic low grade inflammation - Google Patents

Pemirolast for the treatment of systemic low grade inflammation Download PDF

Info

Publication number
CA2780382A1
CA2780382A1 CA2780382A CA2780382A CA2780382A1 CA 2780382 A1 CA2780382 A1 CA 2780382A1 CA 2780382 A CA2780382 A CA 2780382A CA 2780382 A CA2780382 A CA 2780382A CA 2780382 A1 CA2780382 A1 CA 2780382A1
Authority
CA
Canada
Prior art keywords
patient
pemirolast
plasma
treatment
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2780382A
Other languages
English (en)
French (fr)
Inventor
Johan Raud
Carl-Johan Dalsgaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardoz AB
Original Assignee
Cardoz AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardoz AB filed Critical Cardoz AB
Publication of CA2780382A1 publication Critical patent/CA2780382A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2780382A 2009-11-13 2010-11-12 Pemirolast for the treatment of systemic low grade inflammation Abandoned CA2780382A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26094909P 2009-11-13 2009-11-13
US61/260,949 2009-11-13
PCT/GB2010/002096 WO2011058331A1 (en) 2009-11-13 2010-11-12 Pemirolast for the treatment of systemic low grade inflammation

Publications (1)

Publication Number Publication Date
CA2780382A1 true CA2780382A1 (en) 2011-05-19

Family

ID=43479356

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2780382A Abandoned CA2780382A1 (en) 2009-11-13 2010-11-12 Pemirolast for the treatment of systemic low grade inflammation

Country Status (12)

Country Link
US (1) US20120329813A1 (zh)
EP (1) EP2498779A1 (zh)
JP (1) JP2013510837A (zh)
KR (1) KR20120115496A (zh)
CN (1) CN102724982A (zh)
AU (1) AU2010317712A1 (zh)
BR (1) BR112012011231A2 (zh)
CA (1) CA2780382A1 (zh)
EA (1) EA201200720A1 (zh)
IL (1) IL219710A0 (zh)
MX (1) MX2012005513A (zh)
WO (1) WO2011058331A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2720547A1 (en) * 2008-04-07 2009-10-15 Cardoz Ab New combination for use in the treatment of inflammatory disorders
WO2016102941A1 (en) 2014-12-22 2016-06-30 Rspr Pharma Ab New combination of pemirolast and montelukast
KR102096204B1 (ko) * 2019-05-31 2020-04-02 최명석 국소지방 파괴 방법 및 국소지방 파괴용 저장성 용액

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2621640C (en) 2005-09-16 2013-10-29 Daiichi Sankyo Company, Limited Optically active diamine derivative and process for producing the same
EP2120919B1 (en) * 2006-12-18 2012-08-29 Cardoz AB New combination for use in the treatment of inflammatory disorders
EP2107907B1 (en) * 2006-12-20 2012-02-01 Cardoz AB Combination of pemirolast and ramatroban for use in the treatment of inflammatory disorders
WO2009007679A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist
WO2009007673A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a ppar gamma agonist
WO2009122182A1 (en) * 2008-04-04 2009-10-08 Cardoz Ab New combination for use in the treatment of inflammatory disorders
CA2720547A1 (en) * 2008-04-07 2009-10-15 Cardoz Ab New combination for use in the treatment of inflammatory disorders
SI2443120T1 (sl) * 2009-06-16 2017-04-26 Rspr Pharma Ab Kristalna oblika pemirolasta

Also Published As

Publication number Publication date
KR20120115496A (ko) 2012-10-18
WO2011058331A1 (en) 2011-05-19
AU2010317712A1 (en) 2012-05-24
EP2498779A1 (en) 2012-09-19
MX2012005513A (es) 2012-06-19
IL219710A0 (en) 2012-07-31
CN102724982A (zh) 2012-10-10
BR112012011231A2 (pt) 2016-04-05
EA201200720A1 (ru) 2013-02-28
US20120329813A1 (en) 2012-12-27
JP2013510837A (ja) 2013-03-28

Similar Documents

Publication Publication Date Title
US6669955B2 (en) Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
JP4870888B2 (ja) 心血管の病態の予防におけるレニン−アンギオテンシン系阻害剤の使用
AU2002336419A1 (en) Combination dosage form containing a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
EP1663395A1 (en) Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent
US20170202839A1 (en) Crystalline Form of Pemirolast
US20120329813A1 (en) Pemirolast for the Treatment of Systemic Low Grade Inflammation
US20110092463A1 (en) Combination for use in the treatment of inflammatory disorders
WO2012125379A1 (en) Compositions, process of preparation of said compositions and method of treating inflammatory diseases
Kurata et al. Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia
US20050065184A1 (en) Method of reducing the risk of oxidative stress
EP1438043A2 (en) Method of reducing type 2 diabetes in high risk patients
US20070185065A1 (en) Combination therapy for coronary artery disease
KR20240040767A (ko) His 저감반응자의 치료
US20160250217A1 (en) Crystalline form of pemirolast
AU2002362897A1 (en) Method of reducing type 2 diabetes in high risk patients

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20141112